Loading
Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
172 trials on record are attached to one of the types below rather than to Skin cancer (all types) itself. They are grouped by the type that holds them, so someone still working out which type they have can see the whole field from here.
Query for this cancer: (TITLE:"Skin cancer" OR ABSTRACT:"Skin cancer" OR TITLE:"all types" OR ABSTRACT:"all types" OR TITLE:"Skin Cancer" OR ABSTRACT:"Skin Cancer" OR TITLE:"Skin cancers" OR ABSTRACT:"Skin cancers" OR TITLE:"Cutaneous malignancies" OR ABSTRACT:"Cutaneous malignancies" OR TITLE:"Keratinocyte cancer" OR ABSTRACT:"Keratinocyte cancer") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Skin cancer (all types), not a curated reading list.
117 basal cell carcinomas marked in 2 mm increments before Mohs surgery showed that 4 mm clears more than 95 per cent of tumours under 2 cm; the 1992 companion study did the same for squamous cell carcinoma and gave 4 mm, or at least 6 mm for high-risk tumours.
347 patients randomised at the Institut Gustave Roussy: four-year failure 0.7 against 7.5 per cent and a better cosmetic result after surgery on four of five independent judgements. The comparison has never been repeated.
Mohs surgery better for recurrent facial basal cell carcinoma (2.4 against 12.1 per cent) and not significantly better for primary tumours; the ten-year report in 2014 found 4.4 against 12.2 per cent for primary tumours with 56 per cent of recurrences after year five.
The first checkpoint inhibitor and the first BRAF inhibitor, the two routes that transformed melanoma.
First hedgehog pathway inhibitor.
Pembrolizumab and nivolumab approved for advanced melanoma, later moving to adjuvant and neoadjuvant use.
501 people randomised in the United Kingdom; clinical success at three years 84 against 98 per cent and at five years 82.5 against 97.7 per cent.
Five-year results of the 601-patient Dutch trial: tumour-free survival 80.5 per cent with imiquimod, 70.0 with fluorouracil and 62.7 with methyl aminolevulinate photodynamic therapy.
415 patients randomised after surgery and radiotherapy; 24-month disease-free survival 87.1 against 64.1 per cent with adjuvant cemiplimab.